Edwards Lifesciences (EW)

• Market cap: $41.7B
• 1 day: -0.25%
• 5 days: 0.25%
• 1 month: -0.85%
• 3 months: -4.35%
• 6 months: 7.61%
• Year to date: -2.18%
• 1 year: -25.69%
• 5 years: 8.66%
• 10 years: 195.63%
• Sector: Healthcare
• Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies

About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Employees: 15,800

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

122% more call options, than puts

Call options by funds: $586M | Put options by funds: $264M

67% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]

27% more first-time investments, than exits

New positions opened: 180 | Existing positions closed: 142

17% more capital invested

Capital invested by funds: $31.9B [Q3] → $37.5B (+$5.53B) [Q4]

4.83% more ownership

Funds ownership: 80.2% [Q3] → 85.02% (+4.83%) [Q4]

1% more funds holding

Funds holding: 1,181 [Q3] → 1,198 (+17) [Q4]

31% less repeat investments, than reductions

Existing positions increased: 345 | Existing positions reduced: 497

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $60 16% downside
• Avg. target: $77 9% upside
• High target: $90 27% upside

8 analyst ratings

• positive: 3 38%
• neutral: 4 50%
• negative: 1 13%

Barclays Matt Miksic 59% 1-year accuracy 24 / 41 met price target	27% upside $90	Overweight Maintained	13 Feb 2025
Canaccord Genuity William Plovanic 51% 1-year accuracy 24 / 47 met price target	0% downside $71	Hold Maintained	13 Feb 2025
RBC Capital Shagun Singh 63% 1-year accuracy 42 / 67 met price target	20% upside $85	Outperform Reiterated	12 Feb 2025
Piper Sandler Adam Maeder 64% 1-year accuracy 9 / 14 met price target	3% upside $73	Neutral Maintained	12 Feb 2025
Evercore ISI Group Vijay Kumar 38% 1-year accuracy 18 / 47 met price target	3% upside $73	In-Line Maintained	12 Feb 2025